| Dr Adriane Ann Levin, MD | |
|
900 Cummings Ctr Ste 311t, Beverly, MA 01915-6260 | |
| (978) 225-3376 | |
| Not Available |
| Full Name | Dr Adriane Ann Levin |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 9 Years |
| Location | 900 Cummings Ctr Ste 311t, Beverly, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326429721 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 278856 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Shore Medical Center - | Salem, MA | Hospital |
| Northeast Hospital Corporation | Beverly, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Massachusetts Dermatology Associates, P.c. | 4284864331 | 13 |
| Massderm Billing Pc | 2062837503 | 12 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that data from the Company's third generation recombinant protective antigen (rPA) anthrax vaccine program and its Valortim((R)) anthrax anti-toxin program were presented at the Bacillus - ACT 2009 meeting, August 30 - September 3, 2009, organized by the American Society for Microbiology.
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced it is expanding its therapeutic strategy to include active immunotherapies to treat various cancers. The Company will focus on establishing a therapeutic development program based on Adoptive Cell Immunotherapy.
A latest study suggests that children with severe milk allergies may be able to rapidly overcome their sensitivities with the help of a biologic drug that helps to quiet an overly aggressive immune response. This is a small study still waiting to be proved in larger populations say researchers.
Recipients of the 10th annual Communication Awards were announced today by the National Academy of Sciences, National Academy of Engineering, and Institute of Medicine.
The sharing of scientific data in increasingly open ways could benefit cancer research and thus patients, according to a paper published in the peer-reviewed journal ecancermedicalscience.
› Verified 1 days ago
| Entity Name | Massachusetts Dermatology Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396167763 PECOS PAC ID: 4284864331 Enrollment ID: O20140311001042 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that data from the Company's third generation recombinant protective antigen (rPA) anthrax vaccine program and its Valortim((R)) anthrax anti-toxin program were presented at the Bacillus - ACT 2009 meeting, August 30 - September 3, 2009, organized by the American Society for Microbiology.
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced it is expanding its therapeutic strategy to include active immunotherapies to treat various cancers. The Company will focus on establishing a therapeutic development program based on Adoptive Cell Immunotherapy.
A latest study suggests that children with severe milk allergies may be able to rapidly overcome their sensitivities with the help of a biologic drug that helps to quiet an overly aggressive immune response. This is a small study still waiting to be proved in larger populations say researchers.
Recipients of the 10th annual Communication Awards were announced today by the National Academy of Sciences, National Academy of Engineering, and Institute of Medicine.
The sharing of scientific data in increasingly open ways could benefit cancer research and thus patients, according to a paper published in the peer-reviewed journal ecancermedicalscience.
› Verified 1 days ago
| Entity Name | Brigham And Women's Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033535497 PECOS PAC ID: 3870405988 Enrollment ID: O20150107001260 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that data from the Company's third generation recombinant protective antigen (rPA) anthrax vaccine program and its Valortim((R)) anthrax anti-toxin program were presented at the Bacillus - ACT 2009 meeting, August 30 - September 3, 2009, organized by the American Society for Microbiology.
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced it is expanding its therapeutic strategy to include active immunotherapies to treat various cancers. The Company will focus on establishing a therapeutic development program based on Adoptive Cell Immunotherapy.
A latest study suggests that children with severe milk allergies may be able to rapidly overcome their sensitivities with the help of a biologic drug that helps to quiet an overly aggressive immune response. This is a small study still waiting to be proved in larger populations say researchers.
Recipients of the 10th annual Communication Awards were announced today by the National Academy of Sciences, National Academy of Engineering, and Institute of Medicine.
The sharing of scientific data in increasingly open ways could benefit cancer research and thus patients, according to a paper published in the peer-reviewed journal ecancermedicalscience.
› Verified 1 days ago
| Entity Name | Massderm Billing Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033655667 PECOS PAC ID: 2062837503 Enrollment ID: O20200731000650 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that data from the Company's third generation recombinant protective antigen (rPA) anthrax vaccine program and its Valortim((R)) anthrax anti-toxin program were presented at the Bacillus - ACT 2009 meeting, August 30 - September 3, 2009, organized by the American Society for Microbiology.
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced it is expanding its therapeutic strategy to include active immunotherapies to treat various cancers. The Company will focus on establishing a therapeutic development program based on Adoptive Cell Immunotherapy.
A latest study suggests that children with severe milk allergies may be able to rapidly overcome their sensitivities with the help of a biologic drug that helps to quiet an overly aggressive immune response. This is a small study still waiting to be proved in larger populations say researchers.
Recipients of the 10th annual Communication Awards were announced today by the National Academy of Sciences, National Academy of Engineering, and Institute of Medicine.
The sharing of scientific data in increasingly open ways could benefit cancer research and thus patients, according to a paper published in the peer-reviewed journal ecancermedicalscience.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Adriane Ann Levin, MD 900 Cummings Ctr Ste 311t, Beverly, MA 01915-6260 Ph: (978) 225-3376 | Dr Adriane Ann Levin, MD 900 Cummings Ctr Ste 311t, Beverly, MA 01915-6260 Ph: (978) 225-3376 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that data from the Company's third generation recombinant protective antigen (rPA) anthrax vaccine program and its Valortim((R)) anthrax anti-toxin program were presented at the Bacillus - ACT 2009 meeting, August 30 - September 3, 2009, organized by the American Society for Microbiology.
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced it is expanding its therapeutic strategy to include active immunotherapies to treat various cancers. The Company will focus on establishing a therapeutic development program based on Adoptive Cell Immunotherapy.
A latest study suggests that children with severe milk allergies may be able to rapidly overcome their sensitivities with the help of a biologic drug that helps to quiet an overly aggressive immune response. This is a small study still waiting to be proved in larger populations say researchers.
Recipients of the 10th annual Communication Awards were announced today by the National Academy of Sciences, National Academy of Engineering, and Institute of Medicine.
The sharing of scientific data in increasingly open ways could benefit cancer research and thus patients, according to a paper published in the peer-reviewed journal ecancermedicalscience.
› Verified 1 days ago
Lilit Garibyan, M.D, PH.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 900 Cummings Ctr Ste 311t, Beverly, MA 01915 Phone: 978-225-3376 Fax: 978-560-1245 | |
Dr. David S Greenstein, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 138 Conant St, 1st Fl, Beverly, MA 01915 Phone: 978-927-5254 Fax: 978-927-5174 | |
Margaret Dennin Bruns, MD Dermatology Medicare: Medicare Enrolled Practice Location: 900 Cummings Ctr Ste 311t, Beverly, MA 01915 Phone: 978-225-3376 | |
Sabina Bis, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 900 Cummings Ctr Ste 311t, Beverly, MA 01915 Phone: 978-225-3376 | |
Gary S Rogers, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 85 Herrick St, Oncology Center, Beverly, MA 01915 Phone: 978-524-7933 Fax: 978-524-7954 | |
Dr. Robb J Marchione, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 138 Conant St, 1st Floor, Beverly, MA 01915 Phone: 978-927-5254 Fax: 978-921-1418 |